Navigation Links
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
Date:4/27/2011

ct candidates and research and clinical programs now underway or planned, the likelihood and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that may be superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with the sanofi-aventis Group and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2010.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.

Bayer Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.  Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.  These factors include those discussed in Bayer's public reports which are available on the Bayer website at '/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
2. Regeneron Announces Presentation at the 10th Annual Needham Healthcare Conference
3. Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
4. Regeneron Announces March 2011 Investor Conference Presentations
5. Regeneron Submits Biologics License Application to FDA for VEGF Trap-Eye for Treatment of Wet Age-Related Macular Degeneration
6. Regeneron Reports Full Year and Fourth Quarter 2010 Financial and Operating Results
7. Regeneron to Webcast Investor Briefing on VEGF Trap-Eye Clinical Program on Sunday, February 13th at 9 am ET
8. Regeneron Announces Presentation at the ISI Annual Conference
9. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
10. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
11. Christine A. Poon Elected to Regeneron Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Research and Markets  has ... Neurotechnology: 2014-2018" report to their offering. ... most comprehensive and up-to-date publication available covering the neurotechnology ... technology, markets, competitors, and growth rates in four key ... through 2018. It forecasts the number of systems to ...
(Date:9/22/2014)... Sept. 22, 2014 Research and Markets ... and Other Novel Hypercholesterolemia Drugs" report to their ... is a high cholesterol burden despite the presence of ... the available options, statins have been ubiquitously prescribed over ... of plasma LDL cholesterol (LDLC) is the cornerstone of ...
(Date:9/22/2014)... , September 22, 2014 Persistence ... on "Global Market Study on Ophthalmic Devices: ... the global ophthalmic devices market was valued at USD 29,171.5 million ... CAGR of 6.5% from 2014 to 2020, to reach ... Browse the full Global Market Study on Ophthalmic ...
Breaking Medicine Technology:The Market for Neurotechnology: 2014-2018 2PCSK9 and Other Novel Hypercholesterolemia Drugs 2PCSK9 and Other Novel Hypercholesterolemia Drugs 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5
... , COCKEYSVILLE, Maryland, November 2 ... Iron Phosphate Technology,to New Levels. , ... high-tech,batteries for industry, has expanded its range of lithium technologies ... phosphate,cell on the market. These large cells are designed for ...
... Shire plc (LSE: SHP, Nasdaq: SHPGY ... a major medical meeting from a Phase IIIb study of ... (methylphenidate transdermal system) in adolescents aged 13 to 17 years ... In addition, data regarding the pharmacokinetic profile of Daytrana in ...
Cached Medicine Technology:Saft Develops Super-Phosphate(TM) Technology for Rigorous Defense Applications 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 2Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 3Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 4Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 5Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 6Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD 7
(Date:9/22/2014)... Steven Reinberg HealthDay ... Pediatricians are urging that all children aged 6 months and ... American Academy of Pediatrics updated their influenza vaccine recommendations to ... of vaccine to build immunity. The AAP also wants parents ... kids the nasal spray vaccine instead of the flu shot ...
(Date:9/22/2014)... today became a founding partner in the Global STEM ... promoting young talent in science, technology, engineering and math ... York Academy of Sciences (NYAS), Malaysian Prime Minister Najib ... Sept. 22. , With the goal of developing over ... by 2020, the initiative will create a host of ...
(Date:9/22/2014)... 2014 This Flash Report is a ... needs for the Prostate Cancer market. , Download the ... strategies for any launching Prostate Cancer product:, ... an increasingly crowded market , Understanding stakeholder ... identifying community-based thought leaders and stakeholders ,Download the ...
(Date:9/22/2014)... London, UK (PRWEB) September 22, 2014 ... growth in the recent years. The statistically important data ... and safety of cancer vaccines. The primary challenge to ... sufficient information about the exact mechanism of how a ... leads to various results in different individuals owing to ...
(Date:9/22/2014)... -- Two new prescription devices approved by the U.S. ... for people with migraine headaches who don,t tolerate migraine ... device -- the Cefaly -- is designed to prevent ... is meant to be used when migraines first start, ... been looking for alternative migraine treatments. Because these devices ...
Breaking Medicine News(10 mins):Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 2Health News:Pediatricians Urge Flu Vaccine for All Kids 6 Months and Older 3Health News:Growing scientists: World's future jobs are rooted in STEM 2Health News:Growing scientists: World's future jobs are rooted in STEM 3Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Noninvasive Devices May Help Migraines, FDA Says 2
... or two,have a significantly lower risk of having a ... epidemiologists at the University at Buffalo have shown. ... in the study who reported being,intoxicated at least once ... a heart attack than abstainers, results showed. ...
... authorities in Vietnam confirmed Wednesday the possibility that a resident ... have contracted the lethal H5N1 strain of the bird flu ... ,A fresh outbreak of bird flu has hit five ... H5N1 strain after being hospitalized in serious condition. ...
... drinking water, researchers said. ,There are strong grounds ... can reduce the risk of heart attacks. ... it is a wrong belief that tea leads to dehydration. ... antioxidants. It does not dehydrate you, Mirror quoted Ruxton, as ...
... that combination asthma therapy, SYMBICORT leads to significant ... greater patient-reported satisfaction with asthma treatment, versus ... ,SYMBICORT is a recently approved, combination therapy ... in patients 12 years of age and older. ...
... researcher at the Biodesign Institute at Arizona State University has ... stability and functions in comparison with the ones that occurred ... claims to have evolved several new proteins in a fraction ... ,The new findings have led to some surprisingly new ...
... researcher has revealed that fish possessed the genes associated with ... with limbs (tetrapods) came onto the scene about 365 ... in the Nature, Dr Marcus Davis said, the findings overturned ... was a novel evolutionary event and required the descendents of ...
Cached Medicine News:Health News:Moderate Drinking Lowers Women's Risk of Heart Attack 2Health News:Combo Therapy may Be Highly Beneficial in Asthma Control 2Health News:Genes Associated With Limb Development is More Primitive Than Believed 2
... of fibre bronchoscopy: The HF-compatible V series ... other fibre bronchoscopes are measured., ,The ... including the FB-19TV, FB-18V and FB-15V models ... the pediatric FB-8V, offer much better image ...
... High performance fiberoptic imaging from ... ,Olympus has improved its fiberscope range, ... specifications and enhanced image performance. Olympus ... instruments for diagnosis and therapy in ...
... performance fiberoptic imaging from the latest ... improved its fiberscope range, focussing on ... enhanced image performance. Olympus has a ... diagnosis and therapy in the respiratory ...
Slim bronchoscope designed for paediatric applications....
Medicine Products: